Objectives: To evaluate the benefit of fluconazole prophylaxis in preventing i nvasive fungal infection in very low birth weight (VLBW) infants with central va scular access. Study design: A 3-year baseline period (19...Objectives: To evaluate the benefit of fluconazole prophylaxis in preventing i nvasive fungal infection in very low birth weight (VLBW) infants with central va scular access. Study design: A 3-year baseline period (1998 to 2000)was compare d with a subsequent 3-year period (2001 to 2003) during which a different proto col for preventing invasive fungal infection was used. All infants with a birth weight < 1500 g and with central vascular access were eligible for the study. Fl uconazole (Diflucan R)was administered for 28 days at a dose of 6 mg/kg every th ird day during the first week and daily after the first week. Results: There wer e no significant differences between the baseline and the fluconazole groups in demographic characteristics or risk factors for fungal infection. Fungal infecti on developed in 9 of the infants in the baseline group and in none of those in t he fluconazole group (P = .003). A trend of decreasing mortality rate between th e 2 groups (12.6%vs 8.1%; P = .32) was observed but was not statistically sign ificant. No adverse effects of fluconazole therapy were documented. Conclusions: Fluconazole prophylaxis appeared to be beneficial in preventing invasive fungal infection in VLBW infants.展开更多
文摘Objectives: To evaluate the benefit of fluconazole prophylaxis in preventing i nvasive fungal infection in very low birth weight (VLBW) infants with central va scular access. Study design: A 3-year baseline period (1998 to 2000)was compare d with a subsequent 3-year period (2001 to 2003) during which a different proto col for preventing invasive fungal infection was used. All infants with a birth weight < 1500 g and with central vascular access were eligible for the study. Fl uconazole (Diflucan R)was administered for 28 days at a dose of 6 mg/kg every th ird day during the first week and daily after the first week. Results: There wer e no significant differences between the baseline and the fluconazole groups in demographic characteristics or risk factors for fungal infection. Fungal infecti on developed in 9 of the infants in the baseline group and in none of those in t he fluconazole group (P = .003). A trend of decreasing mortality rate between th e 2 groups (12.6%vs 8.1%; P = .32) was observed but was not statistically sign ificant. No adverse effects of fluconazole therapy were documented. Conclusions: Fluconazole prophylaxis appeared to be beneficial in preventing invasive fungal infection in VLBW infants.
